Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

BLOGS
Home›BLOGS›Besponsa (inotuzumab ozogamicin) a new FDA approved drug

Besponsa (inotuzumab ozogamicin) a new FDA approved drug

By admin
September 14, 2017
496
0
Share:

Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC).

Besponsa is specifically indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Besponsa is supplied as a solution for intravenous injection. The recommended dose schedule is as follows:

For the first cycle: the recommended total dose of Besponsa for all patients is 1.8 mg/m2 per cycle, administered as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity.

For subsequent cycles: In patients who achieve a CR or CRi, the recommended total dose of Besponsa is 1.5 mg/m2per cycle, administered as 3 divided doses on Day 1 (0.5 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. OR  In patients who do not achieve a CR or CRi, the recommended total dose of Besponsa is 1.8 mg/m2 per cycle given as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment.

For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with Besponsa is 2 cycles. A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles.

For patients not proceeding to HSCT, additional cycles of treatment, up to a maximum of 6 cycles, may be administered.

Please see drug label for specific dose modifications based on toxicities.

Clinical Results

FDA Approvals

The FDA approval of Besponsa was based on a randomized trial of 326 patients with relapsed or refractory B-cell ALL who had received one or two prior treatments. Patients were randomized to receive treatment with Besponsa or an alternative chemotherapy regimen. The trial measured the percentage of patients with no evidence of disease and full recovery of blood counts after treatment (complete remission or CR). Of the 218 evaluated patients, 35.8 percent who received Besponsa experienced CR for a median 8.0 months; of the patients who received alternative chemotherapy, 17.4 percent experienced CR for a median 4.9 months.

Side Effects

Adverse effects associated with the use of Besponsa may include, but are not limited to, the following:

  • thrombocytopenia
  • neutropenia
  • infection
  • anemia
  • leukopenia
  • fatigue
  • hemorrhage
  • pyrexia
  • nausea
  • headache
  • febrile neutropenia
  • transaminases increased
  • abdominal pain
  • gamma-glutamyltransferase increased
  • hyperbilirubinemia

The Besponsa drug label includes a boxed warning that severe liver damage (hepatotoxicity), including blockage of veins in the liver (veno-occlusive disease [VOD] or sinusoidal obstruction syndrome), occurred in some patients who took Besponsa.

Mechanism of Action

Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22.  The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of inotuzumab ozogamicin is due to the binding of the ADC to CD22-expressing tumor cells, followed by internalization of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death.

 

Tagsantibody-drug conjugate.B-cell precursor acute lymphoblastic leukemiahematopoietic stem cell transplant
Previous Article

Useful websites and online educational support.

Next Article

DUAL CONTROL OF PHARMACY EDUCATION IN INDIA

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

admin

Related articles More from author

  • BLOGS

    Steps to control Imbalanced Hormones Naturally

    October 5, 2017
    By admin
  • Phama news

    MYOCARDIAL INFRACTION

    December 27, 2019
    By Sriram Nagarajan
  • Phama news

    HORMONE THERAPY IN WOMEN

    January 18, 2020
    By Sriram Nagarajan
  • BLOGS

    New malaria drug AQ-13 found effective in human trial

    September 14, 2017
    By admin
  • BLOGS

    IPC 2017 : Indian Pharmaceutical Congress

    September 19, 2017
    By admin
  • BLOGS

    NEW TOOL FOR THE IDENTIFICATION OF MALARIA

    October 24, 2017
    By admin

Leave a reply Cancel reply

You may interested

  • BLOGS

    Stem cell therapy for congestive heart failure

  • Medical & Health

    A trial finds new revolution in migraine treatment

  • Design

    There make for Sixth that multiply blessed two divide creeping

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • October 20, 2020

    List of UGC Approved journals 2020

  • August 8, 2020

    LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

  • June 4, 2020

    UGC-Cancelled-List of journals

  • June 1, 2020

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

Latest Comments

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action started

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

    By admin
    August 8, 2020
  • Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

    By Sriram Nagarajan
    June 8, 2020
  • UGC-Cancelled-List of journals

    By admin
    June 4, 2020
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • FDA approved new drugs 2017

    By admin
    July 16, 2015
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action created
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action started
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.